Antibiotic Resistance Market is Growing Successfully at a Promising CAGR of 5.8% During Forecast 2019-2025
Market Highlights:
According to MRFR analysis, the global Antibiotic Resistance Market is expected to register a CAGR of
5.8% during the forecast period of 2019 to 2025 and was valued
at USD 8,120 million in 2018.
The growth of global antibiotic
resistance market is driven by various factors such as - Rising antibiotic drug resistance infections, rise in the incidence
of chronic and infectious disease, increase in clinical developments of
antibiotic resistance, and rise in global initiatives to control
drug-resistance
Several
market players currently dominate the global antibiotic resistance market. The key
players are involved in product launches and strategic collaborations to
strengthen their market positions.
Key
Players:
·
Achaogen
·
MELINTA THERAPEUTICS
·
Nabriva Therapeutics plc
·
PARATEK therapeutics
·
Seres Therapeutics
·
Theravance Biopharma
·
Tetraphase Pharmaceuticals
·
Basilea Pharmaceutica Ltd
·
Entasis Therapeutics
·
NEMESIS BIOSCIENCE LTD
·
Procarta Biosystems
·
Allecra Therapeutics
Segmentation:
·
The
global antibiotic resistance market has been segmented based on drug class,
disease, pathogen, and end user.
·
The
market, based on drug class, has been divided into cephalosporins, Combination
therapies, tetracyclines,
lipoglycopeptides, oxazolidinones, and others. The combination therapies segment
is likely to be the largest growth during the review period due to the increased
usage of these therapies for gram-negative infections.
·
The global antibiotic
resistance market has been bifurcated, based on disease, into complicated
urinary tract infections, bloodstream infections, complicated intra-abdominal
infections, clostridium difficile infections, acute bacterial and skin
structure infections, hospital-acquired bacterial pneumonia/ventilator,
community-acquired bacterial pneumonia, and others.
·
The global antibiotic
resistance market has been segmented based on pathogen into staphylococcus
aureus, streptococcus pneumoniae, acinetobacter, enterococcus, Hemophilus
influenzae, pseudomonas aeruginosa, clostridium difficile, K. pneumoniae, campylobacter,
and others.
·
The end user segment of the antibiotic
resistance market includes hospitals & clinics, research organizations, and
others.
Regional Analysis:
The
market has been divided, by region, into the Americas, Europe, Asia-Pacific,
and the Middle East & Africa. The Americas is expected to be the largest
market owing to the rising growth in the pharmaceutical sector. The antibiotic
resistance market in the Americas has further been branched into North America
and Latin America, with the North American market divided into the US and
Canada. The European antibiotic resistance market has been categorized as Western
Europe and Eastern Europe. The Western European market has further been
classified as Germany, France, the UK, Italy, Spain, and the rest of Western
Europe. The antibiotic resistance market in Asia-Pacific has been segmented
into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
Increasing healthcare expenditure has boosted the growth of the antibiotic
resistance market; the market in Asia-Pacific is expected to be the fastest-growing.
The antibiotic resistance market in the Middle East & Africa has been
divided into the Middle East and Africa.
Comments
Post a Comment